The explanatory role of stroke as a mediator of the mortality risk difference between older adults who initiate first-versus second-generation antipsychotic drugs

American Journal of Epidemiology

Volumn 180, Issue 8, 2014, Pages 847-852

  Jackson, John W ^a,b,c   Van Der Weele, Tyler J ^a   Viswanathan, Anand ^d   Blacker, Deborah ^a,c   Schneeweiss, Sebastian ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Aged; Antipsychotic drugs; Cerebrovascular disease; Death; Mediation analysis; Mortality risk; Pharmacoepidemiology; Stroke

Indexed keywords

FIRST GENERATION ANTIPSYCHOTIC DRUG; NEUROLEPTIC AGENT; SECOND GENERATION ANTIPSYCHOTIC DRUG; UNCLASSIFIED DRUG;

ADULT; BLOOD SYSTEM DISORDER; CONFIDENCE INTERVAL; DISEASE TREATMENT; DRUG DEVELOPMENT; EPIDEMIOLOGY; HEALTH RISK; MENTAL HEALTH; MORTALITY RISK; RISK FACTOR; STROKE;

AGED; ARTICLE; ATTRIBUTABLE RISK; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; DEATH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; OUTCOME ASSESSMENT; RISK ASSESSMENT; UNITED STATES; CLASSIFICATION; DEMENTIA; INSURANCE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; STROKE; VERY ELDERLY;

NEW JERSEY; PENNSYLVANIA; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DEMENTIA; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICARE; RISK FACTORS; STROKE; UNITED STATES;

EID: 84921767497     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu210     Document Type: Article

References (37)

1. Rabins PV, Blacker D, Rovner BW, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry. 2007;164(12 suppl):5-56.
2. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306(12):1359-1369.
3. US Food and Drug Administration. Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm053171.htm. Published April 11, 2005. Accessed September 12, 2014.
4. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-1943.
5. Pratt N, Roughead EE, Ryan P, et al. Antipsychotics and the risk of death in the elderly: an instrumental variable analysis using two preference based instruments. Pharmacoepidemiol Drug Saf. 2010;19(7):699-707.
6. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627-632.
7. Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012;344:e977.
8. Sikirica S, Marino M, Gagne JJ, et al. Risk of death associated with the use of conventional vs. atypical antipsychotic medications: evaluating the use of the Emilia-Romagna Region database for pharmacoepidemiological studies. J Clin Pharm Ther. 2014;39(1):38-44.
9. European Medicines Agency. CHMP Assessment on Conventional Antipsychotics. London, United Kingdom: European Medicines Agency; 2008. http://www.ema.europa. eu/docs/en-GB/document-library/Report/2010/01/WC500054057.pdf. Published November 20, 2008. Accessed November 18, 2013.
10. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002;167(11):1269-1270.
11. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ. 2004;170(9):1395.
12. Jeste DV, Sable JA, Salzman C. Treatment of late-life disordered behavior, agitation, and psychosis. In: Salzman C, ed. Clinical Geriatric Psychopharmacology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:129-170.
13. Wu CS, Wang SC, Gau SS, et al. Association of stroke with the receptor-binding profiles of antipsychotics-a case-crossover study. Biol Psychiatry. 2013;73(5):414-421.
14. Laredo L, Vargas E, Blasco AJ, et al. Risk of cerebrovascular accident associated with use of antipsychotics: populationbased case-control study. J Am Geriatr Soc. 2011;59(7):1182-1187.
15. Kleijer BC, van Marum RJ, Egberts AC, et al. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol. 2009;23(8):909-914.
16. Sacchetti E, Trifirò G, Caputi A, et al. Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. J Psychopharmacol. 2008;22(1):39-46.
17. Wang PS, Schneeweiss S, Setoguchi S, et al. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol. 2007;27(6):707-710.
18. Kolanowski A, Fick D, Waller JL, et al. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch Psychiatr Nurs. 2006;20(5):217-225.
19. Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr. 2005;17(4):617-629.
20. Huybrechts KF, Schneeweiss S, Gerhard T, et al. Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc. 2012;60(3):420-429.
21. Percudani M, Barbui C, Fortino I, et al. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. J Clin Psychopharmacol. 2005;25(5):468-470.
22. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330(7489):445.
23. Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry. 2005;66(9):1090-1096.
24. Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161(6):1113-1115.
25. Vanderweele TJ, Vansteelandt S. Conceptual issues concerning mediation, interventions and composition. Stat Interface. 2009;2(4):457-468.
26. Valeri L, Vanderweele TJ. Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. Psychol Methods. 2013;18(2):137-150.
27. Commonwealth of Pennsylvania. Pharmaceutical Assistance Contract for the Elderly. 6 Pa Code § 22.21. Harrisburg, PA: Commonwealth of Pennsylvania; 2013. http://www.pacode. com/secure/data/006/006toc.html. Accessed July 1, 2013.
28. State of New Jersey Department of Health. Pharmaceutical Assistance to the Aged and Disabled (PAAD). http://www.state. nj.us/humanservices/doas/home/paaddetail.html. Accessed August 6, 2013.
29. Andrade SE, Harrold LR, Tjia J, et al. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):100-128.
30. Vanderweele TJ, Vansteelandt S. Odds ratios for mediation analysis for a dichotomous outcome. Am J Epidemiol. 2010;172(12):1339-1348.
31. Schneeweiss S, Setoguchi S, Brookhart MA, et al. Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data. CNS Drugs. 2009;23(2):171-180.
32. Chan MC, Chong CS, Wu AY, et al. Antipsychotics and risk of cerebrovascular events in treatment of behavioural and psychological symptoms of dementia in Hong Kong: a hospital-based, retrospective, cohort study. Int J Geriatr Psychiatry. 2010;25(4):362-370.
33. Pratt N, Roughead EE, Salter A, et al. Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review. BMC Med Res Methodol. 2012;12:72.
34. Ogburn EL, VanderWeele TJ. Analytic results on the bias due to nondifferential misclassification of a binary mediator. Am J Epidemiol. 2012;176(6):555-561.
35. Hafeman DM. Confounding of indirect effects: a sensitivity analysis exploring the range of bias due to a cause common to both the mediator and the outcome. Am J Epidemiol. 2011;174(6):710-717.
36. VanderWeele TJ, Chiba Y. Sensitivity analysis for direct and indirect effects in the presence of exposure-induced mediator-outcome confounders. Epidemiol Biostat Public Health. 2014;11(2):e9027.
37. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.